Skip to Main Content

Author Details

Wai-Kwan Alfred Yung
University of Texas M.D. Anderson Cancer Center
1974
377
86
PMIDPaper TitleJournal TitlePublished Year
37935104Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.J Clin Oncol2023
37935104Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.J Clin Oncol2023
36471067The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.Nat Genet2022
35380705Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.Neuro Oncol2022
35474131EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma.Neuro Oncol2022
36471067The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.Nat Genet2022
35380705Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.Neuro Oncol2022
35474131EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma.Neuro Oncol2022
33420056Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation.Nat Commun2021
33738447The promise of DNA damage response inhibitors for the treatment of glioblastoma.Neurooncol Adv2021
33822177Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.Neuro Oncol2021
33130879Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.Neuro Oncol2021
33420056Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation.Nat Commun2021
33433610PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.Neuro Oncol2021
34693288Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.Neurooncol Adv2021
33738447The promise of DNA damage response inhibitors for the treatment of glioblastoma.Neurooncol Adv2021
33822177Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.Neuro Oncol2021
34693288Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.Neurooncol Adv2021
33433610PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.Neuro Oncol2021
33130879Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.Neuro Oncol2021
32166308A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma.Neuro Oncol2020
35665372The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas.J Immunother Precis Oncol2020
31852834<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.Clin Cancer Res2020
31776899A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.J Neurooncol2020
32166308A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma.Neuro Oncol2020
31755915Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.Neuro Oncol2020
33303700Safety and efficacy of magnetic seed localisation of non-palpable breast lesions: pilot study in a Chinese population.Hong Kong Med J2020
33235994Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.Neurooncol Adv2020
33427658Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813.Int J Radiat Oncol Biol Phys2020
33396284Molecular Mechanisms of Treatment Resistance in Glioblastoma.Int J Mol Sci2020
35665372The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas.J Immunother Precis Oncol2020
31755915Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.Neuro Oncol2020
31776899A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.J Neurooncol2020
31852834<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.Clin Cancer Res2020
33427658Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813.Int J Radiat Oncol Biol Phys2020
33303700Safety and efficacy of magnetic seed localisation of non-palpable breast lesions: pilot study in a Chinese population.Hong Kong Med J2020
33396284Molecular Mechanisms of Treatment Resistance in Glioblastoma.Int J Mol Sci2020
33235994Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.Neurooncol Adv2020
30951926Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center.Eur J Cancer2019
31748746Longitudinal molecular trajectories of diffuse glioma in adults.Nature2019
31815044BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening.Am J Cancer Res2019
30926639Prospective Clinical Sequencing of Adult Glioma.Mol Cancer Ther2019
31416846Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma.Cancer Res2019
30951926Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center.Eur J Cancer2019
31497354Wild-type <i>TP53</i> defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs.Am J Cancer Res2019
31815044BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening.Am J Cancer Res2019
31748746Longitudinal molecular trajectories of diffuse glioma in adults.Nature2019
31416846Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma.Cancer Res2019
31497354Wild-type <i>TP53</i> defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs.Am J Cancer Res2019
30926639Prospective Clinical Sequencing of Adult Glioma.Mol Cancer Ther2019
  • 1 - 50 of 754

Recommended Authors

Joanna J Phillips
University of California san francisco
Career Start Year 2006
Number of shared co-authors 54
Nicholas Butowski
University of California san francisco
Career Start Year 2005
Number of shared co-authors 29
Adam M Sonabend
Northwestern University
Career Start Year 2005
Number of shared co-authors 20
Catherine P Langford
University of Alabama at Birmingham
Career Start Year 2005
Number of shared co-authors 1
Matthias Preusser
Medical University of Vienna
Career Start Year 2003
Number of shared co-authors 31
Thomas J Kaley
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 28
Martin Glas
University Hospital Essen
Career Start Year 2002
Number of shared co-authors 8
Andrew P Morokoff
Clinical Sciences Building, The University of Melbourne, The Royal Melbourne Hospital
Career Start Year 2001
Number of shared co-authors 2
W K Alfred Yung
The University of Texas MD Anderson Cancer Center
Career Start Year 2000
Number of shared co-authors 17
Naoki Shinojima
Kumamoto University Hospital
Career Start Year 2000
Number of shared co-authors 17
Timothy E Van Meter
Virginia Commonwealthy University
Career Start Year 1998
Number of shared co-authors 20
John A Boockvar
Lenox Hill Hospital
Career Start Year 1997
Number of shared co-authors 2
H-J Su Huang
Regeneron Pharmaceuticals Inc.
Career Start Year 1994
Number of shared co-authors 6
Jeremy N Rich
UPMC Hillman Cancer Center, University of Pittsburgh Medical Center
Career Start Year 1992
Number of shared co-authors 36
Frank B Furnari
University of California San Diego
Career Start Year 1992
Number of shared co-authors 25
Donald M O'Rourke
Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
Career Start Year 1991
Number of shared co-authors 11
G??nther Stockhammer
Medical University of Innsbruck
Career Start Year 1990
Number of shared co-authors 5
Roger Stupp
Northwestern University
Career Start Year 1990
Number of shared co-authors 36
Johan M Kros
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1988
Number of shared co-authors 33
Motoo Nagane
Kyorin University Faculty of Medicine
Career Start Year 1988
Number of shared co-authors 8
Christine Marosi
Medical University of Vienna
Career Start Year 1987
Number of shared co-authors 10
Camilo E Fadul
University of Virginia Health System
Career Start Year 1987
Number of shared co-authors 3
Ryo Nishikawa
Saitama Medical University International Medical Center
Career Start Year 1986
Number of shared co-authors 25
William A Weiss
University of California san francisco
Career Start Year 1985
Number of shared co-authors 41
Robert Aiken
Rutgers Cancer Institute of New Jersey, Rutgers University
Career Start Year 1984
Number of shared co-authors 17
Joshua B Rubin
Washington University in St. Louis
Career Start Year 1983
Number of shared co-authors 26
Mark W Kieran
Boston Children's Hospital and Harvard Medical School
Career Start Year 1982
Number of shared co-authors 27
Takashi Shingu
The University of Texas MD Anderson Cancer Center
Career Start Year 1979
Number of shared co-authors 22
George Yancey Gillespie
Heersink School of Medicine, The University of Alabama at Birmingham
Career Start Year 1970
Number of shared co-authors 25
Vincent Peter Collins
Mount Sinai Hospital
Career Start Year 1943
Number of shared co-authors 34

Collaborators

Michael D Prados
University of California san francisco
Co-authored papers 60
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Co-authored papers 46
Patrick Y Wen
Co-authored papers 45
Timothy F Cloughesy
David Geffen School of Medicine, University of California Los Angeles
Co-authored papers 44
Juan Fueyo
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 43
Dimpy Koul
The University of Texas MD Anderson Cancer Center
Co-authored papers 42
Kenneth Aldape
National Cancer Institute
Co-authored papers 41
Candelaria Gomez-Manzano
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 41
John F de Groot
Co-authored papers 34
Minesh P Mehta
Co-authored papers 32
Vinay K Puduvalli
The University of Texas MD Anderson Cancer Center
Co-authored papers 28
Morris D Groves
The University of Texas MD Anderson Cancer Center
Co-authored papers 26
John G Kuhn
Co-authored papers 23
Gregory N Fuller
MD Anderson Cancer Center
Co-authored papers 22
Howard Colman
Huntsman Cancer Institute, University of Utah
Co-authored papers 22
Howard A Fine
Meyer Cancer Center
Co-authored papers 21
Frederick F Lang
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 19
Raymond Sawaya
The University of Texas M.D. Anderson Cancer Center, American University of Beirut
Co-authored papers 16
Marta M Alonso
CIMA-Universidad de Navarra
Co-authored papers 15
David Schiff
University of Virginia School of Medicine
Co-authored papers 14
Siyuan Zheng
Greehey Children's Cancer Research Institute
Co-authored papers 13
Roel G W Verhaak
Yale School of Medicine
Co-authored papers 11
Wei Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 11
Tom Mikkelsen
Ontario Brain Institute
Co-authored papers 10
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 10
Jun Yao
The University of Texas MD Anderson Cancer Center
Co-authored papers 9
Henry S Friedman
Co-authored papers 9
Erik P Sulman
NYU Grossman School of Medicine
Co-authored papers 9
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
Yiling Lu
Co-authored papers 7
Release 1.2